JDRF and the Macquarie Group Foundation continue their support of excellence and innovation in type 1 diabetes research with the Type 1 Diabetes Global Research Innovation Awards. These awards recognise innovative researchers who can influence research advances and develop global collaboration in the field of type 1 diabetes.
The Type 1 Diabetes Global Research Innovation Awards encourage the establishment of new connections between international research groups to build a global network of researchers focussed on developing innovative therapies for people with type 1 diabetes.
The winner will receive up to AUD$5000 to independently undertake short-term (up to 4 weeks) research that will influence their approach in addressing the focus of their work. The collaborating research group must be located internationally, and must provide the winner with important new skills and expertise to further their research.
Examples of such work may include, but is not restricted to:
- Learning new research techniques at a collaborating research laboratory
- Presenting research in domestic or international institutions, that will create or build upon relationships between research groups
- Undertaking research in a collaborating group that is renowned for its specialised work
- This Award is open to Australian applicants to collaborate with a research group outside of Australia, or international applicants to collaborate with an Australian research group.
- Applicants must be appropriately qualified (PhD, MB BS or equivalent).
- Applicants must hold a current position at an approved institution or organisation at the time of application
All applicants are evaluated on the following criteria:
- Quality of the research, its relevance to the global JDRF research priorities and ability to contribute towards improving the lives of people with type 1 diabetes
- Quality of the applicant and their potential to gain prominence in influencing the field of type 1 diabetes research
- Value of the award in contributing towards improving the applicant’s skills and expertise for innovative research advances in type 1 diabetes.
Applications Close 11:59pm, Sunday 21st June 2015.
Download Application Form
Previous Award Winners
Australian Award Winner: Dr Stuart Mannering, St Vincent's Institute of Medical Research, Melbourne, Australia
The focus of Dr Mannering’s research is to develop immune-therapies to prevent or treat type 1 diabetes (T1D). He seeks to identify the targets on β-cells that cause T-cells to identify them as a threat. He has recently discovered that these T-cells recognise “proinsulin”, insulin’s precursor. The next stage of this research is to find out what the T-cells do next that causes β-cells to be destroyed.
This award will allow Dr Mannering to visit three international laboratories noted for innovative T1D and immune-based research. There, he will learn new and innovative techniques for studying T-cell responses and build important international collaborations which will further his research into this important area.
Read more about Dr Stuart Mannering here.
International Award Winner: Dr Hanna Skärstrand, Lund University Diabetes Centre, Malmo, Sweden
"My dissertation last year identified that a genetic mutation on a protein (known as ZnT8) changes its shape, making it easier for the ZnT8 autoantibodies to bind to the protein, which could be part of the reason for changes in the immune response. I never thought my projects would continue though, and it’s with thanks to JDRF and winning this Innovation Award that I have been able to continue with this study."
"Since winning the award, we have established a new collaboration between our team of type 1 diabetes researchers at Lund University, Sweden and the Autoimmunity Research Laboratory lead by Dr Michael W Jackson at the Department of Immunology at Flinders University, South Australia. I am incredibly excited to kick-start the collaboration by visiting their lab in mid-March. We hope that this will lead to new insights about the origin of the ZnT8 autoantibodies and their possible role in the ongoing autoimmune response."
Read more about Dr Hanna Skarstrand here.